Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131)

scientific article published on 15 May 2018

Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131) is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3802/JGO.2018.29.E77
P932PMC publication ID6078893
P698PubMed publication ID30022637

P50authorToru HachisugaQ89276958
Shintaro YanazumeQ89841413
Satomi AiharaQ90326437
Akira FujishitaQ90326441
Shuichi TaniguchiQ90326444
Hiroaki KobayashiQ90326449
Kimio UshijimaQ90326451
Shin NishioQ54249184
P2093author name stringMototsugu Shimokawa
Masatoshi Yokoyama
Fumihiro Murakami
Fumitaka Numa
Naofumi Okura
Kohei Kotera
Naoyuki Toki
P2860cites workMajor clinical research advances in gynecologic cancer in 2013Q24562146
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive reviewQ28081186
International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice.Q30317561
Antiemetics: American Society of Clinical Oncology clinical practice guideline updateQ34030613
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceQ34121232
Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.Q35082647
Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatmentQ35350242
The Antiemetic 5-HT3 Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In VivoQ35454299
Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with PalonosetronQ35904224
Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chQ36004950
Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancerQ36205615
Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonistQ36616499
Palonosetron as an anti-emetic and anti-nausea agent in oncology.Q36663660
Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trialQ36729483
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapyQ37111164
Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapyQ37375653
Advances in the management of recurrent endometrial cancerQ38114284
Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trialsQ38192940
Review of Recommended Treatment of Uterine CarcinosarcomaQ38587635
Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatinQ39010204
Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxisQ39453505
The influence of symptoms of disease and side effects of treatment on compliance with cancer therapyQ40782212
Quality of life consequences of chemotherapy-induced emesisQ41080940
Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomitingQ41116408
The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitroQ41969040
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotheQ43191959
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetronQ44592616
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetronQ44667127
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical studyQ44754098
Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjectsQ44854827
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trialQ46168564
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapyQ46448765
NCCN Guidelines Insights: Antiemesis, Version 2.2017.Q47572768
Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm studyQ47870600
Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.Q50980250
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.Q52836736
Measuring chemotherapy-induced nausea and emesis.Q53379104
Validation and Psychometric Assessment of a Short Clinical Scale to Measure Chemotherapy-Induced Nausea and Vomiting: The MASCC Antiemesis ToolQ60732056
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapyQ83967286
The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II StudyQ87631928
P433issue5
P921main subjectgynecologic oncologyQ5625186
(3aS)-palonosetronQ419841
dexamethasoneQ422252
chemotherapyQ974135
P304page(s)e77
P577publication date2018-05-15
P1433published inJournal of gynecologic oncologyQ26842232
P1476titleEfficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131)
P478volume29